|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM358141168 |
| 003 |
DE-627 |
| 005 |
20231226074119.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||chi c |
| 024 |
7 |
|
|a 10.3760/cma.j.cn112140-20230131-00067
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1193.xml
|
| 035 |
|
|
|a (DE-627)NLM358141168
|
| 035 |
|
|
|a (NLM)37312462
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a chi
|
| 100 |
1 |
|
|a Jiang, J J
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Short-term efficacy of empagliflozin in children with glycogen storage disease type Ⅰb
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 15.06.2023
|
| 500 |
|
|
|a Date Revised 15.06.2023
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Objective: To analyze the short-time efficacy of empagliflozin in the treatment of glycogen storage disease type Ⅰb (GSD Ⅰb). Methods: In this prospective open-label single-arm study, the data of 4 patients were collected from the pediatric department in Peking Union Medical College Hospital from December 2020 to December 2022. All of them were diagnosed by gene sequencing and had neutropenia. These patients received empagliflozin treatment. Their clinical symptoms such as height and weight increase, abdominal pain, diarrhea, oral ulcer, infection times, and drug applications were recorded at 2 weeks, 1 month, 2 months, 3 months, 6 months, 9 months, 12 months, and 15 months after treatment to assess the therapeutic effect. The liquid chromatography-tandem mass spectrometry method was used to monitor the changes in 1, 5-anhydroglucitol (1, 5AG) concentration in plasma. At the same time, adverse reactions such as hypoglycemia and urinary tract infection were closely followed up and monitored. Results: The 4 patients with GSD Ⅰb were 15, 14, 4 and 14 years old, respectively at the beginning of empagliflozin treatment, and were followed up for 15, 15, 12 and 6 months, respectively. Maintenance dose range of empagliflozin was 0.24-0.39 mg/(kg·d). The frequency of diarrhea and abdominal pain decreased in cases 2, 3, and 4 at 1, 2 and 3 months of treatment, respectively. Their height and weight increased at different degrees.The absolute count of neutrophils increased from 0.84×109, 0.50×109, 0.48×109, 0.48×109/L to 1.48×109, 3.04×109, 1.10×109, 0.73×109/L, respectively. Granulocyte colony-stimulating factor was gradually reduced in 1 patients and stopped in 3 patient. Plasma 1, 5 AG levels in 2 children were significantly decreased after administration of empagliflozin (from 46.3 mg/L to 9.6 mg/L in case 2, and from 56.1 mg/L to 15.0 mg/L in case 3). All 4 patients had no adverse reactions such as hypoglycemia, abnormal liver or kidney function, or urinary system infection. Conclusion: In short-term observation, empagliflozin can improve the symptoms of GSD Ⅰb oral ulcers, abdominal pain, diarrhea, and recurrent infection, also can alleviate neutropenia and decrease 1, 5AG concentration in plasma, with favorable safety
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a empagliflozin
|2 NLM
|
| 650 |
|
7 |
|a HDC1R2M35U
|2 NLM
|
| 700 |
1 |
|
|a Zheng, X
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ma, M S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cui, X G
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jian, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tang, X Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bao, X D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, S M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ma, J R
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Song, H M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Qiu, Z Q
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Zhonghua er ke za zhi = Chinese journal of pediatrics
|d 1960
|g 61(2023), 6 vom: 02. Juni, Seite 515-519
|w (DE-627)NLM136249191
|x 0578-1310
|7 nnns
|
| 773 |
1 |
8 |
|g volume:61
|g year:2023
|g number:6
|g day:02
|g month:06
|g pages:515-519
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.3760/cma.j.cn112140-20230131-00067
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_50
|
| 912 |
|
|
|a GBV_ILN_61
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_227
|
| 912 |
|
|
|a GBV_ILN_244
|
| 912 |
|
|
|a GBV_ILN_285
|
| 912 |
|
|
|a GBV_ILN_294
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_665
|
| 912 |
|
|
|a GBV_ILN_813
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 61
|j 2023
|e 6
|b 02
|c 06
|h 515-519
|